Overwater Ventures

Thank you Alexis Kayser at Newsweek for doing a sit down with our CEO, Fawad Butt, in the weekly newsletter in the Pulse Check section, Executive Perspectives on key industry issues https://lnkd.in/gnMrdmXt Thanks to: Thanks to: Mark Caron, CHCIO, FACHE, Missy Krasner, Peter Longo, Abigail Crenshaw, Jenna Garbars, Terry McMann, Kishore Ayyadevara, Vamsi Bhandaru, Srinivas Raju Rudraraju, Mike Espy, Kristina Simmons, Imraan Ahmed

Beyond honored to be featured in Forbes / ForbesWomen. Thank you so much, Dilan Gomih, for sharing our story! 🩵 BeSound was founded by women, backed by (many) women, for women. And I'm endlessly inspired by the powerhouse women behind us: Assia Grazioli-Venier, Rachel Springate, Lavinia Errico, Victoria Treyger, Carolyn Witte, Ariel Ganz, Sheila Lirio Marcelo, Brem Rachel, Deena Shakir, Kristina Simmons, and many more.

💰 Adaptyx Biosciences has raised $14 million in seed funding led by Interlagos, bringing total funding to $23 million. Overwater Ventures participated significantly in the round, joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub Network, Hyperlink Ventures, Cantos Ventures I LP, Humba Ventures, and Seaside Ventures. The California-based company is developing a wearable patch for continuous monitoring of multiple biomarkers including hormones, small molecules, electrolytes, drugs, and proteins. 🔬 💬 “Healthcare suffers from a data deficit. Lab tests are only snapshots of health and don’t capture the body’s changing physiology, leaving blind spots that prevent addressing many of today’s health challenges. Adaptyx gives patients and clinicians a continuous view of what’s happening inside the body, transforming previously unseen molecular signals into empowering insights.” Vijit Sabnis, Ph.D., CEO and co-founder of Adaptyx Biosciences 👉 Full story: https://lnkd.in/g7Y249yk #femtech #womenshealth #womenshealthinnovation #health #healthcare #healthtech #healthcareinnovation #healthtech #medtech #medicaldevice #investment #hormonehealth #athometesting #start #vc #venturecapital #investor

💰 Adaptyx Biosciences has raised $14 million in seed funding led by Interlagos, bringing total funding to $23 million. Overwater Ventures participated significantly in the round, joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub Network, Hyperlink Ventures, Cantos Ventures I LP, Humba Ventures, and Seaside Ventures. The California-based company is developing a wearable patch for continuous monitoring of multiple biomarkers including hormones, small molecules, electrolytes, drugs, and proteins. 🔬 💬 “Healthcare suffers from a data deficit. Lab tests are only snapshots of health and don’t capture the body’s changing physiology, leaving blind spots that prevent addressing many of today’s health challenges. Adaptyx gives patients and clinicians a continuous view of what’s happening inside the body, transforming previously unseen molecular signals into empowering insights.” Vijit Sabnis, Ph.D., CEO and co-founder of Adaptyx Biosciences 👉 Full story: https://lnkd.in/g7Y249yk #femtech #womenshealth #womenshealthinnovation #health #healthcare #healthtech #healthcareinnovation #healthtech #medtech #medicaldevice #investment #hormonehealth #athometesting #start #vc #venturecapital #investor

Overture Life is opening a Dallas Clinical and Operational Facility, our first U.S. laboratory and the new hub for AI-supported, non-invasive embryo testing. From this site, fertility teams will gain molecular data that helps guide embryo selection without requiring a biopsy, offering patients a safer and more consistent #IVF experience. It will also serve as Overture's U.S. clinical operations headquarters. Overture Life CEO Hans Gangeskar said: “The central U.S. location facilitates national logistics while giving us access to the biomedical engineering and data science talent concentrated in Texas.” The facility's design accommodates expanded laboratory services and continued advancement of AI-driven automation protocols, including building a continuously learning, regulated automation layer, which is the infrastructure that makes AI-driven IVF reproducible, measurable, and clinically validated. Hafsa Irfan , Head of Clinical Operations for the Dallas facility, added, “The infrastructure we're establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States.” We are also hiring for positions across product development, clinical operations, laboratory operations, manufacturing, quality assurance, regulatory affairs, and commercial functions at the Dallas facility. For Dallas and the IVF community, this milestone signals a new phase where automation becomes the backbone of consistent, accessible fertility treatment. Read more in the press release: https://lnkd.in/gnhy84UN

Highlighting another exciting role from one or our portfolio companies. Gameto is redefining reproductive health and aging and is seeking a strong marketing leader. This role will lead brand, creative, digital, community & more, to support a company truly shaping the future of health! https://lnkd.in/gHfC9HUJ

Thanks San Francisco Business Times for speaking with our CEO & Co-Founder Vijit Sabnis. https://lnkd.in/excuTBdY

🚀 Adaptyx Raises $14M to Launch Wearable Platform for Continuous Molecular Monitoring We’re thrilled to announce our $14 million seed financing, led by Interlagos with participation from Overwater Ventures, Stanford University, the Chan Zuckerberg Biohub Network, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures. — bringing our total funding to $23 million since inception. At Adaptyx Biosciences, we’re building the first wearable platform for continuous, multi-analyte molecular monitoring — going far beyond glucose to track the full spectrum of human biochemistry: small molecules, electrolytes, hormones, drugs, and proteins. Healthcare today captures snapshots. Your body is streaming continuously. Adaptyx transforms those invisible molecular signals into real-time, actionable insights — turning data into a living layer of care that helps detect changes early, guide treatment, and personalize health decisions before problems arise. 💡 Our proprietary molecular switch technology, developed over 17 years at Stanford University and the Chan Zuckerberg Biohub, enables continuous, precise measurement of hundreds of biomarkers in real time. By pairing this with AI-powered analytics, we’re redefining what continuous health data can mean for patients, clinicians, and personalized medicine. This funding will help us accelerate R&D, expand our molecular switch pipeline, and advance ongoing clinical studies toward our first application in heart failure management — while scaling our team across engineering, data science, and clinical operations. A huge thank you to our investors, collaborators, and the brilliant team at Adaptyx who made this milestone possible. 👉 Read our press release and learn more about Adaptyx: https://lnkd.in/gqeRWXx7 Check out our new website: https://adaptyx.bio/ #HealthTech #Biowearables #ContinuousMonitoring #AI #MolecularBiology #PrecisionMedicine #Adaptyx

⚡️ Exclusive! Adaptyx Biosciences, a Menlo Park, Calif.-based developer of a biowearable device to help manage illness and treatment, raised a $14 million seed round. Interlagos led the seed, and Overwater Ventures, Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures participated. Initial use cases for Adaptyx's device include patients managing congestive heart failure, hormone dysregulation, diabetes and hypertension. More in Axios Pro Deals: https://lnkd.in/gBcc3ZKw

We backed Adaptyx Biosciences at pre-seed because the body’s signals shouldn’t stay hidden between lab visits. Continuous measurement of multiple biomarkers can fundamentally change how we understand and act on our health. Adaptyx just announced $23M in total funding, giving patients and clinicians real-time access to their own biology through programmable molecular biosensors. Continuous biomarkers open a window into why actions and patterns affect our health, and what we can do to change them. Tracking analytes across metabolic, renal, and hormonal health unlocks powerful use cases, from therapeutic drug monitoring to fertility, menopause, metabolic disorders and so much more. This is the next generation of continuous monitoring, expanding what wearables can do by adding molecular visibility to the mix. Read Why We Invested Here: